Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia
Author:
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2008.00850.x/fullpdf
Reference20 articles.
1. Standards of medical care in diabetes 2006;American Diabetes Association;Diabetes Care,2006
2. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes;Nathan;Diabetologia,2006
3. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes;Ahren;J Clin Endocrinol Metab,2004
4. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed -cell function in patients with type 2 diabetes;Mari;J Clin Endocrinol Metab,2005
5. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients;Balas;J Clin Endocrinol Metab,2007
Cited by 95 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes;Journal of Diabetes Investigation;2024-04-27
2. Prusogliptin (DBPR108) monotherapy in treatment‐naïve patients with type 2 diabetes: A randomized, double‐blind, active and placebo‐controlled, phase 3 study;Diabetes, Obesity and Metabolism;2024-01-15
3. Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2022-11-30
4. Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus;BMC Medicine;2020-11-16
5. Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis;Endocrinology, Diabetes & Metabolism;2019-11-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3